[go: up one dir, main page]

WO1997011683A3 - Stabilised phospholipid compositions - Google Patents

Stabilised phospholipid compositions Download PDF

Info

Publication number
WO1997011683A3
WO1997011683A3 PCT/GB1996/002364 GB9602364W WO9711683A3 WO 1997011683 A3 WO1997011683 A3 WO 1997011683A3 GB 9602364 W GB9602364 W GB 9602364W WO 9711683 A3 WO9711683 A3 WO 9711683A3
Authority
WO
WIPO (PCT)
Prior art keywords
stabilised
phospholipid compositions
phospholipid
compositions
ammonia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB1996/002364
Other languages
French (fr)
Other versions
WO1997011683A2 (en
Inventor
Kari Dyvik
Harald Dugstad
Roald Skurtveit
Jo Klaveness
Jonny Oestensen
Kiyoto Yachi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Daiichi Pharmaceutical Co Ltd
GE Healthcare AS
Original Assignee
Daiichi Pharmaceutical Co Ltd
Nycomed Imaging AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pharmaceutical Co Ltd, Nycomed Imaging AS filed Critical Daiichi Pharmaceutical Co Ltd
Priority to JP09513213A priority Critical patent/JP2000515487A/en
Priority to EP96931893A priority patent/EP0857070A2/en
Publication of WO1997011683A2 publication Critical patent/WO1997011683A2/en
Publication of WO1997011683A3 publication Critical patent/WO1997011683A3/en
Priority to NO981340A priority patent/NO981340L/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Colloid Chemistry (AREA)
  • Cosmetics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The stability of phospholipid compositions is enhanced by the inclusion of a buffer system comprising ammonia or a water soluble amine having a pH at 15 °C of less than or equal to 9.5.
PCT/GB1996/002364 1995-09-27 1996-09-25 Stabilised phospholipid compositions Ceased WO1997011683A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP09513213A JP2000515487A (en) 1995-09-27 1996-09-25 Stabilized phospholipid composition
EP96931893A EP0857070A2 (en) 1995-09-27 1996-09-25 Stabilised phospholipid compositions
NO981340A NO981340L (en) 1995-09-27 1998-03-24 Stabilized phospholipid compositions

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9519654.9A GB9519654D0 (en) 1995-09-27 1995-09-27 Stabilised phospholipid compositions
GB9519654.9 1995-09-27

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US09043575 A-371-Of-International 1998-07-13
US09/982,196 Continuation US20020039556A1 (en) 1995-09-27 2001-10-19 Stabilised phospholipid compositions

Publications (2)

Publication Number Publication Date
WO1997011683A2 WO1997011683A2 (en) 1997-04-03
WO1997011683A3 true WO1997011683A3 (en) 1997-06-26

Family

ID=10781317

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB1996/002364 Ceased WO1997011683A2 (en) 1995-09-27 1996-09-25 Stabilised phospholipid compositions

Country Status (7)

Country Link
EP (1) EP0857070A2 (en)
JP (1) JP2000515487A (en)
CN (1) CN1202830A (en)
CA (1) CA2233135A1 (en)
GB (1) GB9519654D0 (en)
NO (1) NO981340L (en)
WO (1) WO1997011683A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4752987B2 (en) * 2000-10-12 2011-08-17 ライオン株式会社 External preparation composition
WO2007129311A2 (en) * 2006-05-04 2007-11-15 Pan Sci Tech S.A. Nano-particles with contrast agents for diagnostic delivery system for x-ray and ct
KR101565624B1 (en) * 2007-12-20 2015-11-03 노파르티스 아게 Method for making contact lenses
JP5299449B2 (en) * 2011-02-23 2013-09-25 ライオン株式会社 External preparation composition
CN104561156B (en) * 2013-10-28 2020-07-07 丰益(上海)生物技术研发中心有限公司 Process for preparing saturated phospholipids
GB201821049D0 (en) * 2018-12-21 2019-02-06 Ge Healthcare As Ultrasound contrast agent and methods for use therof
WO2024199424A1 (en) * 2023-03-30 2024-10-03 上海济煜医药科技有限公司 Phospholipid composition, preparation method therefor and use of nitrogen-containing compound

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260811A2 (en) * 1986-08-21 1988-03-23 Vestar, Inc. Phospholipid particles encapsulating polyene antibiotics for the treatment of systemic fungal infections
US4962022A (en) * 1986-09-22 1990-10-09 Becton Dickinson And Company Storage and use of liposomes
WO1990014074A1 (en) * 1989-05-22 1990-11-29 Vical, Inc. Improved liposomal formulations of nucleotides and nucleotide analogues
WO1995026205A1 (en) * 1994-03-28 1995-10-05 Nycomed Imaging A/S Liposomes

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0260811A2 (en) * 1986-08-21 1988-03-23 Vestar, Inc. Phospholipid particles encapsulating polyene antibiotics for the treatment of systemic fungal infections
US4962022A (en) * 1986-09-22 1990-10-09 Becton Dickinson And Company Storage and use of liposomes
WO1990014074A1 (en) * 1989-05-22 1990-11-29 Vical, Inc. Improved liposomal formulations of nucleotides and nucleotide analogues
WO1995026205A1 (en) * 1994-03-28 1995-10-05 Nycomed Imaging A/S Liposomes

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
M. GRIT ET LA: "Hydrolysis of Partially saturated Egg Phosphatidylcholine in Aqueous Liposome Dispersions and the Effect of Cholesterol Incorporation on Hydrolysis Kinetics", JOURNAL OF PHARMACY AND PHARMACOLOGY, vol. 45, no. 6, June 1993 (1993-06-01), pages 490 - 495, XP000196747 *

Also Published As

Publication number Publication date
NO981340D0 (en) 1998-03-24
WO1997011683A2 (en) 1997-04-03
GB9519654D0 (en) 1995-11-29
EP0857070A2 (en) 1998-08-12
CN1202830A (en) 1998-12-23
CA2233135A1 (en) 1997-04-03
JP2000515487A (en) 2000-11-21
NO981340L (en) 1998-03-24

Similar Documents

Publication Publication Date Title
EP0698031A4 (en) SIALYL ANALOGS Le x USEFUL AS CELL ADHESION INHIBITORS
EP0809499A4 (en) SOME IMIDAZOLE 1,4,5-TRISUBSTITUDE COMPOUNDS USEFUL AS CYTOKINE
TW324028B (en) A cleaner composition used in the process of producing semiconductor device
DK0850221T3 (en) Meta-guanidine, urea, thiourea or azacyclic aminobenzoic acid derivatives as intergrin antagonists
EP0992501A3 (en) Pyridonecarboxylic acid derivatives as antibacterial agents
CA2227901A1 (en) Improved cement admixture product
AU6691194A (en) N'-heterocyclyl-n-benzofuranyl urea derivatives and their analogs as acat inhibitors
NZ505163A (en) Sustained release medicinal compositions comprising an ionic compound with an opposite charge to the ionic active substance
AU5317596A (en) Emulsified, low ph cosmetic compositions having improved stability
AU5453894A (en) Antibacterial mouthwash
PL322165A1 (en) Perentereral pharmaceutic compositions containing alkyl ammonium salts of 2-alkylpropionic acids
CA2144583A1 (en) Aqueous based drilling fluid additive and composition
WO2001072263A3 (en) Use of ectoin or ectoin derivatives for protecting stress proteins in the skin
EP0941999A3 (en) Preparation of azithromycin dihydrate
AU2001287904A1 (en) Granulated hydrophobic additive for gypsum compositions
WO1997011683A3 (en) Stabilised phospholipid compositions
BG103648A (en) Paroxetin-containing compositions
CA2047783A1 (en) Stable solution of sodium hypochlorite
AU4765796A (en) Imidazolidinone derivatives as corrosion inhibitors
PT991651E (en) STABILIZED CARBAPENEM INTERMEDIARIES AND SYNTHETIC USE
NZ337798A (en) Pharmaceutical compositions containing lamivudine
AU6893994A (en) Pharmaceutical compositions
EP0668279A3 (en) 6-Azaindole thromboxane synthase inhibitors
AU1969292A (en) Inhibition of scale formation and corrosion by sulfonated organophosphonates
IE872692L (en) Oligopeptide antibiotics

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 96198585.2

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): CA CN JP NO RU US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA CN JP NO RU US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2233135

Country of ref document: CA

Ref document number: 2233135

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1996931893

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1996931893

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996931893

Country of ref document: EP